1h Free Analyst Time
Global Alprazolam Market: About this marketSpeak directly to the analyst to clarify any post sales queries you may have.
The alprazolam market analysis considers sales of alprazolam in Asia, Europe, North America, and ROW. In 2019, the anxiety segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising number of campaigns to raise awareness about anxiety will play a significant role in the anxiety segment to maintain its market position. Also, our global alprazolam market report looks at factors such as increased drug dependency associated with the use of alprazolam, increasing prevalence of anxiety and panic disorders, and low cost of drugs. However, stringent regulatory policies, adverse side effects, and social stigma associated with anxiety and panic disorders may hamper the growth of the alprazolam industry over the forecast period.
Global Alprazolam Market: Overview
Increasing prevalence of anxiety and panic disorders
The global alprazolam market is expected to benefit significantly from the strong prevalence of psychiatric indications such as anxiety and panic disorders. The increasing number of campaigns focusing on raising awareness about the severity of anxiety and panic disorders is expected to boost the demand for drugs for the treatment of such indications The prevalence of anxiety and panic disorders is also on the rise in the younger population due to changing lifestyles and increasing stress. As per a study conducted by the NIHI(National Institute of Health), panic disorders are prevalent in approximately 2.9% of the adult population in the US, with the prevalence rate being significantly higher in women than in men. Such factors will lead to the expansion of the global alprazolam market at a CAGR of over 4% during the forecast period.
Use of alprazolam in new research areas
The use of alprazolam was strictly limited to treat anxiety and panic disorders. However, with the growing demand for novel therapeutics for various indications, the research on alprazolam as a potential treatment option for other indications is increasing. Clinical-stage pharmaceutical vendors are collaborating to research alprazolam for the treatment of epilepsy. These vendors are focusing on developing Staccato Alprazolam as a Rapid Epileptic Seizure Termination (REST) therapy for providing relief from acute repetitive seizures. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global alprazolam market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alprazolam manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.
Also, the alprazolam market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
The following companies as the key players in the global alprazolam market: Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the use of alprazolam in new research areas.”
According to the report, one of the major drivers for this market is the increasing prevalence of anxiety and panic disorders.
Further, the report states that one of the major factors hindering the growth of this market is the stringent regulatory policies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amneal Pharmaceuticals Inc.
- Cadila Healthcare Ltd.
- Endo International Plc
- Jazz Pharmaceuticals Plc
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- UCB SA.
